Politics, Government & Business in California's Inland Empire
Wednesday, December 2, 2015 – 08:30 a.m.
Billionaire Businessman Donald Trump has widened his lead in the race for the republican nomination for President of the United States.
December 1, 2015 – 3:09 pm
An attorney and former Marine Corps intelligence officer has announced plans to run against Inland Rep. Raul Ruiz in 2016.
To read post by Jeff Horseman in The P-E Political Empire Blog, click here.
Published: Dec. 1, 2015
Updated: Dec. 2, 2015 7:01 a.m.
The Riverside County District Attorney’s Office has declined to pursue criminal charges against Murrieta Councilman Harry Ramos for his actions during a Murrieta Chamber of Commerce event in January.
To read article by Aaron Claverie in The Press-Enterprise, click here.
Published: Dec. 1, 2015 – Updated: 4:59 p.m.
Both domestic and international passenger traffic at Ontario International Airport increased in October, up more than 5.6 percent. There were 380,584 passengers in October, compared with 360,256 for the same month one year ago.
To read article by Richard K. De Atley in The Press-Enterprise, click here.
By Neil Nisperos, Inland Valley Daily Bulletin
Posted: 12/01/15 – 5:52 PM PST |
Manufacturing in the Inland Empire may be back in growth mode as manufacturers responded positively to questions about the state of their businesses, according to the latest report from the Institute of Applied Research at Cal State San Bernardino.
By Dan Walters
dwalters@sacbee.com
December 1, 2015
For years, the state has conducted something of a shell game to help finance Medi-Cal, its health insurance system for the poor that now covers nearly a third of Californians.
By Sarah Ferris
12/01/15 – 11:05 AM EST
The CEO of UnitedHealthcare on Tuesday said he regretted the decision to enter the ObamaCare marketplace last year, which the company says has resulted in millions of dollars in losses.
By Carolyn Y. Johnson and Brady Dennis
December 1, 2015 at 2:27 PM
–This story has been updated.–
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.